MSD PD-1 inhibitor approved by the US FDA
我放心你带套猛
发表于 2024-1-14 10:06:13
290
0
0
On January 12th local time, Merck announced that the US Food and Drug Administration (FDA) has approved the use of Merck's PD-1 inhibitor Keytruda in combination with radiotherapy and chemotherapy (CRT) for the treatment of stage III-IVA cervical cancer patients defined by the International Federation of Obstetrics and Gynecology (FIGO) 2014.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- Black Friday Quick Report: Online and offline online shopping in the United States is expected to set a new record!
- Delaware judge overturns Musk salary agreement, Tesla says it will appeal
- Merck PD-1 inhibitor pembrolizumab's fourth lung cancer indication approved in China
- Tesla surged last night! Bank of America raises Tesla's 12-month target price to $400 and maintains buy rating
- Weekly Outlook | US CPI may shake expectations of Fed interest rate cuts! Oracle and Broadcom announce their performance, will it affect the subsequent trend of AI concept stocks?
- Merck PD-1 inhibitor CRDA approved for the treatment of locally advanced cervical cancer in China
- Merck PD-1 inhibitor CRDA approved for the treatment of locally advanced cervical cancer in China
- Merck PD-1 inhibitor CRDA approved for the treatment of locally advanced cervical cancer in China
- The US warehouse strike poses challenges to Amazon's holiday shopping season operations
- Sanofi's BTK inhibitor is declared for market in China
